A new num­ber 1 drug? Keytru­da tapped to top the 10 biggest block­busters on the world stage by 2024

An­a­lysts may be fret­ting about Keytru­da’s longterm prospects as a host of ri­val ther­a­pies el­bow their way to the mar­ket. But the folks at Eval­u­ate Phar­ma are con­fi­dent that last year’s $7 bil­lion earn­er is head­ed for glo­ry, tap­ping it to beat out the cur­rent #1 ther­a­py Hu­mi­ra as Ab­b­Vie watch­es that fran­chise swoon over the next 5 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER